On the topic of commercialisation strategies, I came across this old (sponsored) * article from 2018 in which Trevor Lockett talks about co-marketing with pharmaceutical companies. I'm sharing here to highlight the types of fairly complex deals, in particular with regard to pricing, that they may be currently exploring. (the article also mentions timelines that were obviously unmet, which is irrelevant now)
https://unauthorised investment advice/health/could-co-marketing-be-a-way-for-rhythm-bio-to-get-its-test-out-there/
